# US 2022/0325345 A1 · Methods and Compositions for Assessing Patients with Preeclampsia-Related Conditions Using MicroRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0325345 A1
- Document ID: US20220325345A1
- Status: Published application
- Kind: A1
- Application number: 17/592,818
- Filed: 2022-02-04
- Published: 2022-10-13
- Earliest claimed: 0001-01-01
- Assignees: Ewinger, Inc.
- Applicants: Ewinger Inc.
- Inventors: Edward E. WINGER; Jane REED
- Web page: https://patentgrep.com/patent/US20220325345A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.

## Claims

### Claim 1

A method for characterizing a preeclampsia-related condition in a subject comprising:
collecting a first non-placental biological sample;
extracting microRNA-comprising RNA from the first non-placental biological sample;
quantifying at least one microRNA within the extracted RNA; and
comparing the quantification of the at least one microRNA to a quantification of the at least one microRNA from a second, non-placental biological sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one of the first non-placental biological sample and the second non-placental biological sample is taken during a first trimester of pregnancy.

### Claim 3 (depends on 1)

The method of claim 1, wherein at least one of the first non-placental biological sample and the second non-placental biological sample is taken prior to pregnancy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first non-placental biological sample and the second non-placental biological sample bridge a therapeutic treatment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first non-placental biological sample and the second non-placental biological sample bridge a designated period of time.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second non-placental biological sample is a control sample.

### Claim 7 (depends on 1)

The method of claim 1, further comprising identifying existence of the preeclampsia-related condition based, at least in part, on the comparison.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering a treatment based, at least in part, on the comparison.

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-1, hsa-miR-1229, hsa-miR-1244, hsa-miR-1267, hsa-miR-132, hsa-miR-133b, hsa-miR-144-3p, hsa-miR-146a, hsa-miR-148a-3p, hsa-miR-155, hsa-miR-16, hsa-miR-181a, hsa-miR-193a-3p, hsa-miR-196a, hsa-miR-199a-5p, hsa-miR-199b-5p, hsa-miR-210, hsa-miR-219-5p, hsa-miR-221-5p, hsa-miR-223, hsa-miR-301a-3p, hsa-miR-30e-3p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-424-5p, hsa-miR-513a-5p, hsa-miR-hsa-miR-575, hsa-miR-582-5p, hsa-miR-671-3p and hsa-miR-7-5p.

### Claim 10 (depends on 9)

The method of claim 9, further comprising quantifying and comparing at least five microRNAs from the first non-placental biological sample and the second non-placental biological sample.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-223, hsa-miR-7-5p, hsa-miR-148a-3p, hsa-miR-144-3p, hsa-miR-16 and hsa-miR-582-5p.

### Claim 12 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-144-3p, hsa-miR-148a-3p, hsa-miR-582-5p, hsa-miR-301a-3p, hsa-miR-146a, hsa-miR-575, hsa-miR-199a-5p, hsa-miR-133b and hsa-miR-424-5p.

### Claim 13 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-210, hsa-miR-1229, hsa-miR-223, hsa-miR-575 and hsa-miR-340-5p.

### Claim 14 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-1229, hsa-miR-146a, hsa-miR-210, hsa-miR-1244, hsa-miR-132 and hsa-miR-133b.

### Claim 15 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-513a-5p, hsa-miR-193a-3p, hsa-miR-7-5p, hsa-miR-575, hsa-miR-221-5p, hsa-miR-133b, hsa-miR-1 and hsa-miR-199a-5.

### Claim 16 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-513a-5p, hsa-miR-193a-3p, hsa-miR-221-5p, hsa-miR-340-5p, hsa-miR-7-5p, hsa-miR-575, hsa-miR-1, hsa-miR-199a-5p and hsa-miR-33a-5p.

### Claim 17 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-513a-5p, hsa-miR-193a-3p, hsa-miR-7-5p, hsa-miR-575, hsa-miR-221-5p, hsa-miR-133b, hsa-miR-1 and hsa-miR-199a-5p.

### Claim 18 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-575, hsa-miR-144-3p, hsa-miR-148a-3p, hsa-miR-210, hsa-miR-193a-3p, hsa-miR-199b-5p and hsa-miR-199a-5p.

### Claim 19 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of miR575, miR144-3p, miR199a-5p, miR210, miR1229, miR133b, miR148a-3p, miR193a-3p, miR7-5p, miR223 and miR340-5p.

### Claim 20 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-144-3p, hsa-miR-582-5p, hsa-miR-30e-3p, hsa-miR-340-5p, hsa-miR-424-5p, hsa-miR-199a-5p, hsa-miR-199b-5p, hsa-miR-210, hsa-miR-221-5p, hsa-miR-33a-5p, hsa-miR-575, hsa-miR-7-5p, hsa-miR-1229, hsa-miR-1267 and hsa-miR-671-3p.

### Claim 21 (depends on 1)

The method of claim 1, wherein the at least one microRNA is selected from the group consisting of hsa-miR-1181, hsa-miR-1296, hsa-miR-132, hsa-miR-136, hsa-miR-141, hsa-miR-142-5p, hsa-miR-144, hsa-miR-153, hsa-miR-1537, hsa-miR-193a-3p, hsa-miR-196a, hsa-miR-219-5p, hsa-miR-29b, hsa-miR-301a, hsa-miR-32, hsa-miR-33a, hsa-miR-545, hsa-miR-582-3p and hsa-miR-590-5p.

### Claim 22

A diagnostic kit for characterizing a preeclampsia-related condition comprising a microarray including at least five microRNAs selected from the group consisting of hsa-miR-1, hsa-miR-1229, hsa-miR-1244, hsa-miR-1267, hsa-miR-132, hsa-miR-133b, hsa-miR-144-3p, hsa-miR-146a, hsa-miR-148a-3p, hsa-miR-155, hsa-miR-16, hsa-miR-181a, hsa-miR-193a-3p, hsa-miR-196a, hsa-miR-199a-5p, hsa-miR-199b-5p, hsa-miR-210, hsa-miR-219-5p, hsa-miR-221-5p, hsa-miR-223, hsa-miR-301a-3p, hsa-miR-30e-3p, hsa-miR-33a-5p, hsa-miR-340-5p, hsa-miR-424-5p, hsa-miR-513a-5p, hsa-miR-hsa-miR-575, hsa-miR-582-5p, hsa-miR-671-3p and hsa-miR-7-5p.
